Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.
| Revenue (Most Recent Fiscal Year) | $266.96M |
| Net Income (Most Recent Fiscal Year) | $28.51M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.93 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.91 |
| Pre-Tax Margin (Trailing 12 Months) | 41.42% |
| Net Margin (Trailing 12 Months) | 125.90% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -34.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.44 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.43 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.31 |
| Inventory Turnover (Trailing 12 Months) | 3.83 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.39 |
| Earnings per Share (Most Recent Fiscal Year) | $0.25 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.55 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 116.23M |
| Free Float | 106.84M |
| Market Capitalization | $132.50M |
| Average Volume (Last 20 Days) | 1.43M |
| Beta (Past 60 Months) | 0.89 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.08% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |